Multivalent Mycoplasma bacterin
AssigneeHMV Associates, Inc.
InventorsTheo A. Hymas, Cynthia L. Becker
Life of this patent
Estimating the term…
Abstract
The present invention provides a bacterin comprising at least two virulent Mycoplasma bovis isolates of differing biotypes, in an amount sufficient to immunize a calf or cow against infection by Mycoplasma bovis, an adjuvant, and a pharmaceutically acceptable carrier. Further provided is a method of producing the bacterin of the present invention. Finally, the present invention also provides a method of immunizing a calf or cow against Mycoplasma bovis infection, especially infection associated with BRD, comprising administering to the calf or cow a dose of a bacterin made according to the present invention in an amount effective to elicit a protective response in the animal, as evidenced by a decrease in the mortality and morbidity associated with natural infection.
Claims14
A vaccine composition comprising
- a) an immunogenically effective amount of (i) at least two killed Mycoplasma bovis selected from the group consisting of a biotype IV isolate, a biotype V isolate, a biotype VI isolate, and (ii) a killed Mycoplasma alkalescens, wherein said immunogenically effective amount is sufficient to produce a protective response in a vaccinate against Bovine Respiratory Disease resulting from Mycoplasma infection;
- b) an adjuvant;
- and
- c) a pharmaceutically effective carrier.
Dependencies are inferred from the claim text.